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Results of unrelated cord blood transplan-
tation (UCBT) in childhood acute myeloid
leukemia (AML) have not been previously
reported. We analyzed 95 children receiv-
ing UCB transplants for AML (20 in first
complete remission [CR1], 47 in CR2, and
28 in more advanced stage). Poor progno-
sis cytogenetic abnormalities were identi-
fied in 29 cases. Most patients received a
1 or 2 HLA antigens–mismatched UCB
transplants. The median number of col-
lected nucleated cells (NCs) was 5.2  107/
kg. Cumulative incidence (CI) of neutro-
phil recovery was 78%  4%, acute graft-
versus-host disease (GVHD) was 35% 5%,
and 100-day transplantation-related mortal-
ity (TRM) was 20%  4%. In multivariable
analysis, a collected NC dose higher than
5.2  107/kg was associated with a lower
100-day TRM. The 2-year CI of relapse
was 29%  5% and was associated with
disease status. The 2-year leukemia-free
survival (LFS) was 42%  5% (59%  11%
in CR1, 50%  8% in CR2, and 21%  9%
for children not in CR). Children with poor
prognosis cytogenetic features had simi-
lar LFS compared with other patients
(44%  11% vs 40%  8%). In CR2, LFS
was not influenced by the length of CR1
(53%  11% in CR1 < 9.5 months com-
pared with 50%  12% in later relapses).
We conclude that UCBT is a therapeutic
option for children with very poor-
prognosis AML and who lack an HLA-
identical sibling. (Blood. 2003;102:
4290-4297)
© 2003 by The American Society of Hematology
Introduction
Bone marrow transplantation (BMT) from an HLA-matched
sibling or unrelated donor plays a major role in the treatment of
children with relapsed acute myeloid leukemia (AML).1-6 How-
ever, although there are currently more than 8 million donors
registered in marrow donor registries around the world, a
substantial proportion of children who lack a sibling donor will
never undergo BMT from an HLA-matched unrelated donor
either because such a donor cannot be found or because the time
to identify a donor is too long. Moreover, for those children who
received unrelated bone marrow transplants, increased HLA
disparity adversely affects survival because of high risk of
graft-versus-host disease (GVHD) and opportunistic infec-
tions.7-9 The use of haploidentical family donors provides a
potential source of hematopoietic stem cells for children who
lack both a sibling and an unrelated donor.10-11 T-cell depletion
of the graft can in part overcome the risk of severe GVHD, but it
substantially increases the risk of severe and prolonged posttrans-
plantation immunodeficiency.
Hematopoietic stem cells from an unrelated cord blood (UCB)
transplant can restore hematopoiesis and immune function after a
myeloablative conditioning regimen, even if the graft is not
perfectly HLA identical to the recipient.12-15 This important medi-
cal advance led to the establishment of large cord blood banks that
made possible the use of UCB to provide transplants for patients
who lack a conventional related or unrelated donor. In addition,
UCB offers the advantage of significantly faster availability of
banked cryopreserved UCB units compared with the availability of
unrelated bone marrow grafts.16
The efficacy of BMT in AML is at least partially linked to a
graft-versus-leukemia effect (GVL), which is mediated by the
engrafted T lymphocytes and is statistically associated with the
clinical manifestations of graft-versus-host disease (GVHD). GVHD
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is less frequent after UCB transplantation (UCBT) than after
unrelated bone marrow transplantation (UBMT).17 This particular
characteristic of UCBT could raise theoretical concerns about the
efficacy of this kind of transplantation in childhood AML that
cannot currently be clinically clarified because there are very few
data in the literature reporting specific results and prognostic
factors of UCBT in childhood AML. In a previous Eurocord
comparative study of children receiving UCB transplants or
UBM transplants for acute leukemia, relapse rate was not
increased after UCBT.17 However, it was not possible to report
specific data for children with AML at different stages of their
disease because of the relatively small number of patients in
each subgroup. Using data from the Eurocord registry, we are
now able to report outcomes and their association with patient-,
disease-, and transplant-related factors in 95 children who
underwent UCBT for AML.
Patients, materials, and methods
Patients’ selection criteria
All children reported to the Eurocord registry as having undergone
UCBT for AML were included in this study, with the exception of those
with either Down syndrome (n  2) or Fanconi anemia (n  2).
Ninety-five children aged 16 years or younger were analyzed. They
received transplants from 1994 through March 2002 in 49 centers from
17 countries. Approval for this study was obtained from the Eurocord
institutional review board. Informed consent was provided according to
the Declaration of Helsinki.
Patient characteristics
The characteristics of the 95 children are listed in Table 1. Ten of them were
considered as having secondary AML on the basis of a history of previous
exposure to chemotherapy or radiotherapy or a previous history of
myelodysplasia, myeloproliferative disorders, or Blackfan-Diamond anemia.
Abnormal karyotypes were classified in the favorable-risk group if t(8;
21), t(15; 17), or inv(16) was detected. In patients lacking these favorable
changes, the presence of monosomy 7, 11q23 abnormalities other than
t(9;11), monosomy 5, del(5q), abnormal 3q, t(6; 9), or a complex karyotype
defined the poor-risk group. The remaining abnormalities were classified in
the intermediate-risk group.
At time of UCBT, 20 children were in first complete remission (CR1),
47 were in CR2, 5 were in third or subsequent CR, and 23 were in relapse.
Children in CR1 received transplants at a median time of 4 months after
they achieved remission (range,  1 month to 10 months). Nine of them
were in the poor-risk cytogenetic group and 2 had secondary leukemia. In
the subgroup of 47 children who received transplants in CR2, the median
time from CR2 to UCBT was 2 months (range,  1 month to 14 months);
the median duration of CR1 was 9.5 months with only 5 relapses occurring
more than 18 months after CR1.
Twenty-two of the 95 children had previously received hematopoietic
stem cell transplants. Eighteen had relapsed after having received a prior
autologous transplantation. In the 4 remaining cases, UCBT was performed
after engraftment failure of a prior unrelated bone marrow transplantation.
Umbilical cord blood characteristics and transplantation
procedure
HLA-A, -B antigen serologic testing and a low-resolution generic DRB1
oligotyping were available for all cord blood transplants and recipients
(Table 2). In addition, high-resolution allelic DRB1 typing of cord blood
and recipient was performed in 93 of 95 cases. Using HLA-A, -B serology
and high-resolution allelic DRB1 typing, most of the children had either 1
(47%) or 2 (33%) disparities with their graft.
As shown in Table 2, conditioning and GVHD prophylaxis regimens
greatly varied among centers in this retrospective and multicenter study. A
hematopoietic growth factor, most frequently granulocyte colony-
stimulating factor (G-CSF), was started during the early posttransplantation
period (from day 0 to day7) in 47 children.
Statistical methods
For this analysis, we used July 1, 2002, as the reference date (ie, the day at
which all centers locked data on patient outcomes). The median duration of
follow-up was 31 months (range, 3 to 92 months).
The outcome end points were neutrophil recovery, platelet recovery,
GVHD, relapse, transplantation-related mortality (TRM), overall survival
and leukemia-free survival (LFS). Neutrophil recovery was defined by an
absolute neutrophil count (ANC) of at least 0.5 109/L for 3 consecutive
days, the first of these 3 days being used as the recovery day. Platelet
recovery was defined by a nontransfused platelet count of at least
20  109/L for 7 consecutive days. Death, relapse, and infusion of a stem
cell rescue occurring before day 60 or day 180 were considered as
competing risks for neutrophil or platelet recovery, respectively. Graft
failure rates for neutrophil or platelets were calculated for patients living
without relapse or autologous infusion (competing events) more than 60 or
180 days, respectively. Acute and chronic GVHD were diagnosed and
graded at each center according to standard criteria.18,19 Relapse was
Table 1. Patient and disease characteristics of children with AML
given an unrelated cord blood transplant
Patient characteristics
Features at diagnosis
Age, median (range) 4.8 y (1 mo to 15 y)
No. with de novo/secondary AML 85/10
WBC count
No. evaluable 91/95
Median (range) 21.5  109/L (0.8-509  109/L)
No. with WBC greater than 50  109/L (%) 29 (32)
FAB subtype
No. evaluable 89/95
M0/M1/M2/M3 9/9/18/5
M4/M5/M6/M7 16/21/3/8
CNS involvement (%) 4 (4)
Cytogenetics (%)
No. evaluable 81/95
Abnormal 58 (72)
Relatively favorable risk 8 (10)
Intermediate risk 21 (26)
Poor risk 29 (36)
Normal 23 (28)
Features at unrelated cord blood transplantation
Age, median (range) 6 y (4 mo to 16 y)
Recipient’s weight, median (range) 21 kg (4.4-78 kg)
CMV serology
No. evaluable 94/95
Negative (%) 49 (52)
Positive (%) 45 (48)
Status (%)
Standard-risk category
First CR 20 (21)
Second CR 47 (50)
High-risk category
Third or subsequent CR 5 (5)
Without CR 23 (24)
WBC indicates white blood cell; FAB, French-American-British classification;
CNS, central nervous system; CMV, cytomegalovirus; and CR, complete remission.
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defined on the basis of morphologic evidence of leukemia in bone marrow
or other extra-medullary organs. TRM was defined as all causes of
nonleukemic deaths occurring after transplantation. Overall survival was
the time between transplantation and death due to any cause. LFS was
defined as time interval from UCBT to first event, either relapse or death in
complete remission.
These outcomes were all right-censored. For overall survival and LFS,
Kaplan-Meier estimates provided estimated incidence over time, whereas
Cox models were used to evaluate the joint influence of patient-, disease-,
and transplant-related variables on the outcome. However, the other end
points shared a competing risks setting, that is patients could develop events
that avoid the occurrence of the event of interest; as an example, after death
or relapse before engraftment, no recovery and no GVHD could occur.
Therefore, these end points (neutrophil and platelet recovery, acute and
chronic GVHD, relapse, TRM) were analyzed through the use of cumula-
tive incidence curves for estimating incidence over time20 and Fine and
Gray models21 to assess prognostic factors.
Whatever the model, we first fit univariable models that contain each of
the variables (Table 3) one at a time. Secondly, all variables with a P value
below .05 by the likelihood ratio test were included in a multivariable
model. Cause-specific hazard ratios (HRs) were estimated with 95%
confidence intervals. Statistical analysis used the SAS 8.2 (Sas, Cary, NC)
and S-Plus 2000 (MathSoft, Seattle, WA) software packages.
Results
Neutrophil and platelet recoveries
The cumulative incidence (CI) of neutrophil recovery at day 60 was
78% 4% (Figure 1A). During the first 60 days after transplanta-
tion, competing risks for neutrophil recovery were death (n 7),
relapse (n 5), and infusion of a stem cell rescue (n 3). Graft
failure rate for neutrophil recovery was 7.5% (6 of 80 patients). For
those patients who recovered, the median time to achieve an ANC
equal to or more than 0.5 109/L was 26 days (range, 12-57 days).
In the univariable analysis, factors associated with neutrophil
recovery were (1) status of disease at transplantation (cumulative
incidence of neutrophil recovery at day 60 was 87% 4% for
children who received transplants in CR1 or CR2 versus
57% 10% for those with more advanced disease; P  .01); (2)
period of transplantation (63% 10% for patients treated before
January 1998 versus 84% 5% after this date; P  .03); (3)
prophylactic use of hematopoietic growth factors (the cumula-
tive incidence was 83%  6% when a hematopoietic growth
factor was started during the immediate posttransplantation
period versus 73%  7% in the other cases; P  .015, Figure
1B); and (4) methotrexate (MTX) in the GVHD prophylaxis
(63%  10% versus 84%  5% when MTX was not used;
P  .04). The association of neutrophil recovery with the
nucleated cells dose was not statistically significant. In a
multivariable analysis, the factors associated with an improved
neutrophil recovery were standard risk status of disease at
transplantation (CR1 or CR2) and prophylactic use of hematopoi-
etic growth factor (Table 4).
The day-180 CI of platelet recovery was 58% 5% (Figure
2A). During the first 180 days after transplantation, competing
risks for platelet recovery were death (n 18), relapse (n 10),
and infusion of a stem cell rescue (n 4). Graft failure rate was
8.4% for platelet recovery (5 of 59 patients). For those patients who
recovered, the median time to achieve platelet recovery was 52
days (range, 18-171 days). In the univariable and multivariable
analyses (Table 4), the only factor, which was statistically associ-
ated with platelet recovery, was the disease status at time of
transplantation. The incidence of platelet recovery by day 180 was
66% 6% for children who received transplants in CR1 or CR2
compared with 39% 10% in patients who received transplants in
a more advanced phase (P .001). Use of prophylactic hematopoi-
etic growth was not statistically associated with speed of platelet
recovery (Figure 2B).
Acute and chronic GVHD
Acute GVHD (grade II or more) was observed in 34 patients (15
had grade II, 14 grade III, and 5 grade IV). One hundred–day
cumulative incidence of acute GVHD was 35% 5%. We did not
find any patient-, disease-, or transplant-related factor that could be
Table 2. Transplant characteristics of children with AML given
an unrelated cord blood transplant
Unrelated cord blood characteristics
HLA compatibility with the recipient (%)
High-resolution typing
No. evaluable 93/95
Identical 8 (9)
1 HLA disparity 44 (47)
2 HLA disparities 31 (33)
3 or more HLA disparities 10 (11)
Low-resolution typing
No. evaluable 95/95
Identical 13 (14)
1 HLA disparity 52 (55)
2 HLA disparities 28 (29)
3 HLA disparities 2 (2)
ABO compatibility with the recipient
No. evaluable 94/95
Matched 45
Minor incompatibility 24
Major incompatibility 25
Nucleated cells collected/kg recipient
No. evaluable 92/95
Median (range) 5.2  107 (1.2  107-46.6  107)
Nucleated cells infused/kg recipient
No. evaluable 94/95
Median (range) 4.4  107 (0.4  107-36  107)
CD34 infused cells/kg recipient
No. evaluable 60/95
Median (range) 1.38  105 (0.4  105-78  105)
Transplantation characteristics
Conditioning regimen (%)
TBI-containing 44 (46.5)
Bu-containing 47 (49.5)
Miscellaneous 4 (4)
Pretransplantation ATG/ALG or anti-T
MoAb (%)
72 (76)
Posttransplantation growth factor,
started D0-D7 (%)
47 (50)
GVHD prophylaxis (%)
Including cyclosporine A 85 (89.5)
 steroids 63 (66)
MTX 20 (21)
TacrolimusMTX 7 (7.5)
Miscellaneous 3 (3)
TBI indicates total body irradiation; Bu, Busulfan; ATG, antithymocyte globulin;
ALG, antilymphocyte globulin; MoAb, monoclonal antibody; D0-D7, day 0 to day 7
after graft infusion; and MTX, methotrexate.
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associated with the incidence of acute GVHD. Notably, the number
of HLA disparities between cord blood and recipient was not
statistically associated with grades II to IV acute GVHD.
Two years after UCBT, the cumulative incidence of chronic
GVHD was 15% 5%. Nine of 53 patients at risk presented signs
of chronic GVHD (6 limited and 3 extensive).
Early transplant-related mortality
Nineteen patients died of nonleukemic causes during the first 100
days after UCBT (3 of acute GVHD, 13 of infections, and 3 of
other causes). Cumulative incidence of transplantation-related
mortality at day 100 was 20% 4%. In univariable analyses, the
following factors were associated with increased risk of death:
patients older than 6 years of age (31% 7% versus 10% 4%;
P  .025); patient’s weight more than 21 kg (30% 7% versus
11%  5%; P  .048); collected nucleated cell dose lower than
5.2  107/kg (33% 7% versus 9% 4% for patients receiv-
ing more than 5.2 107/kg, P  .013); and infused nucleated cell
dose lower than 4.4 107/kg (30% 7% versus 11% 5%
for those receiving more than 4.4 107/kg, P  .046). There was a
trend toward an increased risk of 100-day TRM when major ABO
incompatibility was present (32% 9% versus 16% 5% in the
other cases, P  .078). In multivariable analysis, the only factor
associated with an increased early TRM was a low collected
nucleated cell dose (less than 5.2 107/kg; Figure 3).
Relapse incidence
Twenty-five patients had hematologic relapse after UCBT and
26 patients died without experiencing disease recurrence. Two-
year cumulative relapse incidence (RI) was 29%  5%. It was
29%  5% in 85 patients with de novo AML and 33%  17% in
10 patients with secondary leukemia. In univariable and multiva-
riable analyses (Table 4), the 2 following features were associ-
ated with increased RI: patient’s weight lower than 21 kg
(16%  6% versus 42%  8%; P  .0001) and status of disease
at transplantation (19%  5% for CR1 and 2 versus 53%  10%
for more advanced disease status; P  .000 43). More precisely,
the 2-year cumulative RI was 10%  7% for patients who
received transplants in CR1, 23%  7% for patients in CR2, 1
of 5 for patients in CR3 or higher, and 61%  11% for patients
who were not in remission at time of UCBT (Figure 4A). The RI
after UCBT in children presenting with poor-risk cytogenetic
abnormalities was 26.5%  10% compared with 31%  6% in
other patients. The absence of previous acute GVHD (grades II to
IV) was not associated with an increased RI (P  .62). In the
subgroup of patients who received transplants in CR2, there was
a trend toward an increased post-UCBT relapse risk for children
who had suffered from an early pre-UCBT relapse (length of
Figure 1. The cumulative incidence of neutrophil recovery. Cumulative incidence
of neutrophil recovery (A) and neutrophil recovery according to use of prophylactic
hematopoietic growth factors (B).
Table 3. Univariable analyses of LFS after UCBT for childhood AML
Two-year Kaplan-Meier estimate of LFS, %* P, log-rank test
Overall 42  5
Diagnosis, de novo vs secondary AML 40  6 vs 56  16 .54
WBC count at diagnosis, less than or equal to 50  109/L vs greater than 50  109/L 43  7 vs 41  10 .67
Cytogenetics, “poor-risk” karyotype vs others 44  11 vs 40  8 .62
Age at UCBT, younger than 6 y vs 6 y or older 44  7 vs 39  6 .67
Recipient’s sex, male vs female 48  7 vs 36  7 .35
Recipient’s weight at UCBT, less than 21 kg vs 21 kg or more 42  6 vs 42  7 .96
Recipient’s CMV serology prior to UCBT, negative vs positive 37  7 vs 48  7 .09
Status at UCBT .002†
CR1 59  11
CR2 50  8
Subsequent CR 0
No CR 21  9
Previous transplantation, no vs yes 38  6 vs 54  11 .10
Graft/recipient HLA compatibility (high-resolution typing) .22
HLA identical 19  15
1 HLA disparity 45  8
2 HLA disparities 37  9
3 or more HLA disparities 56  17
ABO compatibility, matched vs minor vs major mismatched 51  8 vs 42  12 vs 28  9 .05
Collected nucleated cell dose, less than 5.2  107/kg vs 5.2  107/kg or more 38  7 vs 46  8 .46
Infused nucleated cell dose, less than 4.4  107/kg vs 4.4  107/kg or more 36  7 vs 50  8 .25
Infused CD34 cell dose, less than 1.38  105/kg vs 1.38  105/kg or more 34  9 vs 52  10 .35
UCBT date, before January 1998 vs after January 1998 30  9 vs 46  6 .04
Conditioning regimen, Bu-containing vs TBI-containing 33  7 vs 53  8 .10
Posttransplantation growth factor, no vs yes 35  8 vs 48  7 .23
Use of MTX for GVHD prophylaxis, no vs yes 41  7 vs 41  10 .67
WBC indicates white blood cell; CMV, cytomegalovirus; TBI, total body irradiation; Bu, Busulfan; and MTX, methotrexate.
*Values given as percentage SD.
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CR1  9.5 months) when compared with children with later
pre-UCBT relapses (33%  11% versus 12%  9%; P  .09).
Leukemia-free survival, overall survival, and causes of death
Forty-nine patients died: 23 from disease relapse, 3 of GVHD, 18
of infectious complication (bacterial 6, viral 5, fungal 5 and
parasitic 2), 3 of interstitial pneumonitis, and 2 of organ failure.
Estimated 2-year overall survival and leukemia-free survival
were 49% 5% and 42%  5%, respectively. The univariable
analyses of factors considered as potential predictors for 2-year
LFS are detailed in Table 3. As shown in this table, the most
significant factor was status of disease at time of UCBT. Two-year
LFS was 59% 11% for children who received transplants in first
CR, 50% 8% for those in second CR, none among 5 in CR3 or
beyond, and 21% 9% for children who were not in remission at
time of UCBT (Figure 4B). Two other factors had a statistically
significant influence: the date of transplantation and ABO compat-
ibility between donor and recipient, with favorable outcome
occurring in children who received transplants after January
1998 and without major ABO incompatibility. LFS of children
with a poor prognostic karyotype was similar to LFS of other
patients. In the subgroup of 47 children who received trans-
plants while in CR2, LFS was not influenced by the length of
CR1: it was 53%  11% for patients relapsing in the first 9.5
months and 50%  12% for those relapsing later. In multivari-
ate analysis, 2 factors were associated with overall survival and
LFS: status of the disease at transplantation and major ABO
incompatibility (Table 4).
Discussion
This retrospective registry-based analysis is the first, to our
knowledge, that was specifically designed to describe the results of
UCBT in childhood AML. As expected, we found that the outcome
was associated with disease status at time of transplantation.
Precisely, LFS was 59% 11% for children who received trans-
plants in CR1, 50% 8% in CR2, 0 of 5 in CR3 or beyond, and
21% 9% for children who were not in remission at time of
UCBT. The corresponding 2-year relapse incidences were
10% 7%, 23% 7%, 1 of 5 patients, and 61% 11%. These
estimated relapse incidences are comparable to those reported after
BMT from an unrelated HLA-matched donor.2-4 In the Seattle
experience of 161 patients with AML who received unmanipulated
BM transplants from unrelated donors, the cumulative incidences
of relapse were 19% in CR1, 23% in CR2, 25% in subsequent CR,
44% during relapse, and 63% during primary induction failure.2 In
another series reported by Marks et al,4 39 patients with AML
received T-cell–depleted unrelated BM transplants during first or
second CR. Five of these 39 patients (13%) relapsed.
We also analyzed the association of 3 well-identified prognostic
factors of childhood AML such as the karyotype of malignant cells,
de novo or secondary, and the duration of first CR for children who
Figure 2. The cumulative incidence of platelet recovery. Cumulative incidence of
platelet recovery (A) and platelet recovery according to use of prophylactic hemato-
poietic growth factors (B).
Figure 3. Collected nucleated cell dose. Cumulative incidence of 100-day
transplantation-related mortality according to the median number of cells before
freezing per recipient’s weight.
Table 4. Multivariable analyses of risk factors for the main outcomes after UCBT for childhood AML
Factors Hazard ratio (95% confidence interval) P
Neutrophil recovery
CR1-2 at transplantation 2.17 (1.22-3.87) .009
Prophylactic hematopoietic growth factor 1.81 (1.15-2.86) .03
Platelet recovery
CR1-2 at transplantation 2.21 (1.17-4.17) .01
Relapse
Advanced status at transplantation (CR3 or higher, no CR) 3.84 (1.66-8.33) .001
Weight less than 21 kg 2.77 (1.118-6.66) .02
Transplantation-related mortality at day 100
Collected nucleated cell dose less than 5.2  107/kg 4.16 (1.35-12.50) .01
Survival
CR1-2 at transplantation 2.73 (1.53-5) .00066
Major ABO incompatibility 2.07 (1.15-3.84) .015
Leukemia-free survival
CR1-2 at transplantation 2.83 (1.64-5) .00029
Major ABO incompatibility 2.00 (1.14-3.70) .019
CR indicates complete remission.
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received transplants during their second CR. The karyotype of
malignant cells has been shown to be one of the most relevant
predictors of treatment outcome in childhood AML.22-27 In our
study, 36% of the patients with a successful cytogenetic analysis
were classified in the poor-risk cytogenetic category. This unusu-
ally elevated incidence for a pediatric AML population probably
indicates that the patients were selected for their high risk of
treatment failure. Interestingly, children with a poor karyotype had
similar 2-year LFS and a similar incidence of relapse compared
with other patients (44%  11% versus 40%  8% and
26.5% 10% versus 31% 6%, respectively). Children with
secondary leukemia are usually considered as having more aggres-
sive disease than children with de novo AML. Only 10 children in
this study had secondary leukemia but their outcome after UCBT
did not differ from that of children with de novo AML. The length
of first remission has been demonstrated to be a major prognostic
factor for children with relapsed AML.28-29 We tested the potential
influence of the length of first remission in the subgroup of children
that received transplants in CR2 and did not find any correlation
between this variable and LFS, although there was a trend toward a
lower rate of relapse in patients with more prolonged CR1. Taken
together, our results suggest that these 3 prognostic factors,
identified in patients with AML undergoing contemporary chemo-
therapy or standard allogeneic BMT, may not have the same
predictive value in the context of unrelated UCBT. This apparently
potent antileukemic effect in poor-risk AML does not support the
hypothesis of an inadequate GVL effect after UCBT.
In our study, the 100-day cumulative incidence of TRM was
20% 4%. This high incidence is similar to the ones reported in
other series of children receiving UCB transplants.17,30-32 Clearly,
TRM is currently the principal obstacle for a wider use of UCBT in
children with high-risk AML as well as in many other diseases. In
our analysis, TRM was 17% 5% in transplantations carried out
after January 1998 and 30% 9% before this date. Moreover,
when the collected nucleated cell dose was above the median
(5.2 107/kg), the 100-day TRM decreased to 9% 4%. The
same effect on TRM was found when the analyzed variable was the
infused cell dose with a TRM of 11% 5% for children receiving
a cell dose above the median value. The influence of the graft
nucleated cell dose on posttransplantation outcome has been
consistently demonstrated since the first reports of successful
UCBT. Gluckman et al14 first demonstrated that children who
received more than 3.7 107 nucleated cells/kg, the median
infused cell dose in their series, had better outcome than children
who received a lower cell dose. More recently, Wagner et al33
showed that the infused CD34 cell dose was a more potent
indicator of prognosis than the nucleated cell dose. They described
a threshold of 1.7 105 CD34 cells/kg and suggested that UCB
units containing less than this CD34 cell dose should be consid-
ered inadequate to routine use because of a very high TRM risk.33
In fact, whatever the cell dose criteria may be, it probably has to be
interpreted in the context of HLA disparity. Several studies have
recently suggested that the impact of cell dose could be more
significant when the graft/recipient HLA–incompatibility in-
creases.15,33,34 These issues are crucial in the choice of an umbilical
cord transplantation for a given patient but will be more efficiently
addressed in large registry studies than in a disease-specific study
like ours.
Of note, the primary cause of nonleukemic death in our series of
95 children was more frequently infection (n 18 cases) than
GVHD (n  3). The fact that most deaths were secondary to
infections has important implications for the clinical care of
children treated with UCBT. In addition to the choice of a CB graft
with high cell counts, improved prophylaxis, prompter diagnosis,
and treatment of infectious complications may have a major impact
on the outcome of these patients. The relatively low incidence of
lethal GVHD and the high risk of infectious complications raise
questions on the intensity of posttransplantation immunosuppres-
sive therapy. In order to clarify these important issues, carefully
designed prospective trials are needed.
We conclude that UCBT is a good treatment for children with
AML who have a very high risk of treatment failure under
chemotherapy and who lack an HLA-compatible sibling. The
results of UCBT were particularly promising for children with
secondary leukemia, a poor prognosis karyotype, and in children
who received transplants in CR2 after an early relapse.
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Figure 4. Two-year cumulative RI. Cumulative inci-
dence of relapse (A) and probability of leukemia-free
survival (B) according to disease status at unrelated cord
blood transplantations.
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Appendix
Participating centers and number of transplantations reported (childhood AML)
Centers Location Principal Investigator(s) No. of cases
Univ. La Sapienza, and Ospedale Pediatrico Bambini Gesu Rome, Italy Drs W. Arcese, M. Caniglia 8
Children’s Hospital Medical Centre Cincinnati, OH Dr A. Filipovich 5
MD Anderson Cancer Centre Houston, TX Dr K.-W. Chan 5
Hoˆpital Pe´diatrique La Timone Marseille, France Pr G. Michel 4
Sydney Children’ Hospital Randwick, Australia Prs M. Vowels, C. Oswald 4
Hoˆpital d’Enfants Vandoeuvre Nancy, France Pr P. Bordigoni 3
Hospital M infantil Vall d’Hebron Barcelona, Spain Pr J. Orlega 3
The New Children’s Hospital Sydney, Australia Dr P. Shaw 3
BMT Unit Schneider Children’s Petach-Tikva, Israel Drs I. Yaniv, J. Stein 3
Inst Portugues Oncologia Lisboa, Portugal Drs M. Abecassis, A. Machado 2
Hospital Infantil La Fe Valencia, Spain Drs A. Verdeguer, V. Castel 2
FLENI Buenos Aires, Argentina Dr B. Diez 2
Ospedale Regine Margherita Torino, Italy Dr F. Fagioli 2
Hospital Israelita A. Einstein Sao Paulo, Brasil Dr E. Ferreira 2
Hoˆpital Saint Louis Paris, France Pr E. Gluckman 2
Hoˆpital Claude Huriez Lille, France Pr J. P. Jouet 2
IRCC Policlinico San Matteo Pavia, Italy Dr F. Locatelli 2
Hospital de Clinicas Curitiba, Brasil Dr R. Pasquini 2
Inst. Portugues Oncologia Porto, Portugal Dr P. Pimentel 2
City of Hope Medical School Duarte, CA Dr J. Rosenthal 2
FHCRC Seattle, WA Drs E. Sievers, A. Mellon 2
Clinica Oncoematologia Pediatrica Padova, Italy Drs L. Zanesco, C. Messina 2
Univ. Hospital Lund Lund, Sweden Dr A. Bekassy 1
Inst. Paoli Calmette Marseille, France Pr D. Blaise 1
Lombardi Cancer Center Washington, DC Dr M. Cairo 1
Hoˆpital Saint Justine Montreal, QC, Canada Dr M. Champagne 1
Hoˆpital/Cantonal Universitaire Geneva, Switzerland Dr B. Chapuis 1
Inst. G. Gaslini Genova, Italy Dr S. Dallorso 1
Children’s Hospital Oakland Oakland, CA Dr M. Walters 1
Inst. di clinica pediatrica Pisa, Italy Dr C. Favre 1
St Sophia Children’s Hospital Athens, Greece Drs S. Grafakos, J. Peristeri 1
Hoˆpital de I’Archet Nice, France Dr N. Gratecos 1
Medical City Dallas Hospital Dallas, TX RN M. Hooker 1
Tokai Univ. School of Medicine Isehara, Japan Dr S. Kato 1
Prince of Wales Hospital Hong Kong, China Dr C. K. Li 1
Hospital Nino Jesus of Madrid Madrid, Spain Dr L. M. Madero 1
Hospital Infantil La Paz Madrid, Spain Dr A. M. Martinez-Rubio 1
ITMO La Plata, Argentina Dr J. Milone 1
Hadassah Univ. Hospital Jerusalem, Israel Drs A. Nagler, S. Slavin 1
Univ. of Bologna Bologna, Italy Dr A. Pession 1
Hoˆpital La Miletrie Poitiers, France Dr A. Sadoun 1
CETRAMOR Rosario, Argentina Drs J. Saslavski, J. Cozzi 1
Ospedale V Cervello Palermo, Italy Dr R. Scime 1
James Whitcomb Riley Hospital for Children Indianapolis, IN Dr F. Smith 1
Royal Children’s Hospital Melbourne, Australia Dr K. Tiedemann 1
Heinrich-Heine-Univ. Du¨sseldorf, Germany Dr U. Go¨bel 1
Sheffield Children’s Hospital Sheffield, United Kingdom Dr A. Vora 1
Martin Luther Univ.-Wittenberg Ktinik for Kinder Halle, Germany Dr A. Wawer 1
Sapporo Med. Univ. Sapporo, Japan Dr R. Kudo 1
Yokohama City Univ. Yokohama, Japan Dr H. Fujii 1
Kyoto Univ. Kyoto, Japan Dr Tatsutoshi Nakahata, Dr Y.-W. Lin 1
Yamaguchi Univ. Hospital Yamaguchi, Japan Dr H. Ayukawa 1
Ibaragi Prefecture Children’s Hospital Mito, Japan Dr M. Tsuchida 1
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